Members of the serine protease (SP) gene family carry out diverse functional roles in normal mammalian physiology and also contribute significantly to the pathogenesis of disease. Several members of the SP gene family are of relevance for the study of prostate carcinogenesis. Two of these, prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) exhibit an expression profile essentially restricted to the human prostate. Exploiting the tissue compartmentalization of PSA has revolutionized the management of patients with prostate cancer by providing a tool for the early diagnosis and subsequent monitoring of patients with prostate cancer. There is emerging evidence that these prostate serine proteases play a direct physiological role in the pathogenesis of metastatic prostate cancer, and further that these serine proteases can be used as targets for a variety of therapeutic strategies including the targeting of specific cytotoxic compounds to prostate tumor cells and as regents for gene therapy based approaches. We have recently identified two serine proteases, prostase and TMPRSS2, that exhibit a tissue expression pattern with high prostate specificity. This proposal is based on the hypothesis that Progression to metastatic prostate cancer is driven by the increased or ectopic expression of a family of serine protease enzymes expressed in prostate cancer cells. These serine proteases influence metastatic disease through protease action on barriers to invasion (e.g. extracellular matrix) and growth factor systems (e.g. IGF). This proposal will test these hypothesis by accomplishing the following Specific Aims: 1. Characterize the regulation of prostase and TMPRSS2 serine protease gene expression. 2. Identify activators and substrates of the prostates and TMPRSS2 proteins. 3. Develop polyclonal and monoclonal anti-prostase and anti-TMPRSS2 antibodies for the evaluation of protein expression in patient sera and in fixed tissues representing a range of normal, benign, and malignant prostate pathology. 4. Characterize the role of prostase and TMPRSS2 in prostate cancer bone metastasis; 5. Identify and characterize additional serine proteases expressed in the prostate.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA085859-01A2
Application #
6594328
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-05-01
Project End
2007-04-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Don-Doncow, Nicholas; Marginean, Felicia; Coleman, Ilsa et al. (2017) Expression of STAT3 in Prostate Cancer Metastases. Eur Urol 71:313-316
Montgomery, Bruce; Tretiakova, Maria S; Joshua, Anthony M et al. (2017) Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res 23:2169-2176
Martin, P L; Yin, J-J; Seng, V et al. (2017) Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer. Oncogene 36:525-533
Suominen, Mari I; Fagerlund, Katja M; Rissanen, Jukka P et al. (2017) Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 23:4335-4346
Haider, Maahum; Zhang, Xiaotun; Coleman, Ilsa et al. (2016) Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases. Clin Exp Metastasis 33:239-48
Wu, Yu; Davison, Jerry; Qu, Xiaoyu et al. (2016) Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer. Epigenetics 11:247-58
Van Allen, Eliezer M; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget 7:52888-52899
Brocqueville, Guillaume; Chmelar, Renee S; Bauderlique-Le Roy, Hélène et al. (2016) s-SHIP expression identifies a subset of murine basal prostate cells as neonatal stem cells. Oncotarget 7:29228-44
Qu, Xiaoyu; Jeldres, Claudio; Glaskova, Lena et al. (2016) Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence. J Mol Diagn 18:215-24
Wu, Yu; Schoenborn, Jamie R; Morrissey, Colm et al. (2016) High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. J Mol Diagn 18:131-43

Showing the most recent 10 out of 157 publications